Regulatory Measures Could Mitigate Coronavirus Risks In Europe
More Flexible Procedures Will Be Needed, Says Off-Patent Industry
As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.
You may also be interested in...
Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.
Australia’s NeuClone has reported the completion of subject visits in its Phase I trial for a biosimilar ustekinumab rival to Janssen’s Stelara, with favorable results seen ahead of the formal study report that is due in the third quarter of this year.
Average UK trade prices for paracetamol more than trebled in March as the coronavirus outbreak took hold, while the antiviral valaciclovir saw an average increase of over 300%.